EGFR/HER-targeted therapeutics in ovarian cancer

Jason A. Wilken, Tayf Badri, Sarah Cross, Rhoda Raji, Alessandro D. Santin, Peter Schwartz, Adam J. Branscum, Andre T. Baron, Adam I. Sakhitab, Nita Jane Maihle

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Despite decades of research and evolving treatment modalities, survival among patients with epithelial ovarian cancer has improved only incrementally. During this same period, the development of biologically targeted therapeutics has improved survival for patients with diverse malignancies. Many of these new drugs target the human epidermal growth factor receptor (EGFR/HER/ErbB) family of tyrosine kinases, which play a major role in the etiology and progression of many carcinomas, including epithelial ovarian cancer. While several HER-targeted therapeutics are US FDA approved for the treatment of various malignancies, none have gained approval for the treatment of ovarian cancer. Here, we review the published literature on HER-targeted therapeutics for the treatment of ovarian cancer, including novel HER-targeted therapeutics in various stages of clinical development, as well as the challenges that have limited the use of these inhibitors in clinical settings.

Original languageEnglish (US)
Pages (from-to)447-469
Number of pages23
JournalFuture Medicinal Chemistry
Volume4
Issue number4
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Therapeutics
Survival
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplasms
Carcinoma
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Wilken, J. A., Badri, T., Cross, S., Raji, R., Santin, A. D., Schwartz, P., ... Maihle, N. J. (2012). EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry, 4(4), 447-469. https://doi.org/10.4155/fmc.12.11

EGFR/HER-targeted therapeutics in ovarian cancer. / Wilken, Jason A.; Badri, Tayf; Cross, Sarah; Raji, Rhoda; Santin, Alessandro D.; Schwartz, Peter; Branscum, Adam J.; Baron, Andre T.; Sakhitab, Adam I.; Maihle, Nita Jane.

In: Future Medicinal Chemistry, Vol. 4, No. 4, 01.03.2012, p. 447-469.

Research output: Contribution to journalReview article

Wilken, JA, Badri, T, Cross, S, Raji, R, Santin, AD, Schwartz, P, Branscum, AJ, Baron, AT, Sakhitab, AI & Maihle, NJ 2012, 'EGFR/HER-targeted therapeutics in ovarian cancer', Future Medicinal Chemistry, vol. 4, no. 4, pp. 447-469. https://doi.org/10.4155/fmc.12.11
Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P et al. EGFR/HER-targeted therapeutics in ovarian cancer. Future Medicinal Chemistry. 2012 Mar 1;4(4):447-469. https://doi.org/10.4155/fmc.12.11
Wilken, Jason A. ; Badri, Tayf ; Cross, Sarah ; Raji, Rhoda ; Santin, Alessandro D. ; Schwartz, Peter ; Branscum, Adam J. ; Baron, Andre T. ; Sakhitab, Adam I. ; Maihle, Nita Jane. / EGFR/HER-targeted therapeutics in ovarian cancer. In: Future Medicinal Chemistry. 2012 ; Vol. 4, No. 4. pp. 447-469.
@article{436d75a9985b45788114a16f436a6fe6,
title = "EGFR/HER-targeted therapeutics in ovarian cancer",
abstract = "Despite decades of research and evolving treatment modalities, survival among patients with epithelial ovarian cancer has improved only incrementally. During this same period, the development of biologically targeted therapeutics has improved survival for patients with diverse malignancies. Many of these new drugs target the human epidermal growth factor receptor (EGFR/HER/ErbB) family of tyrosine kinases, which play a major role in the etiology and progression of many carcinomas, including epithelial ovarian cancer. While several HER-targeted therapeutics are US FDA approved for the treatment of various malignancies, none have gained approval for the treatment of ovarian cancer. Here, we review the published literature on HER-targeted therapeutics for the treatment of ovarian cancer, including novel HER-targeted therapeutics in various stages of clinical development, as well as the challenges that have limited the use of these inhibitors in clinical settings.",
author = "Wilken, {Jason A.} and Tayf Badri and Sarah Cross and Rhoda Raji and Santin, {Alessandro D.} and Peter Schwartz and Branscum, {Adam J.} and Baron, {Andre T.} and Sakhitab, {Adam I.} and Maihle, {Nita Jane}",
year = "2012",
month = "3",
day = "1",
doi = "10.4155/fmc.12.11",
language = "English (US)",
volume = "4",
pages = "447--469",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "4",

}

TY - JOUR

T1 - EGFR/HER-targeted therapeutics in ovarian cancer

AU - Wilken, Jason A.

AU - Badri, Tayf

AU - Cross, Sarah

AU - Raji, Rhoda

AU - Santin, Alessandro D.

AU - Schwartz, Peter

AU - Branscum, Adam J.

AU - Baron, Andre T.

AU - Sakhitab, Adam I.

AU - Maihle, Nita Jane

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Despite decades of research and evolving treatment modalities, survival among patients with epithelial ovarian cancer has improved only incrementally. During this same period, the development of biologically targeted therapeutics has improved survival for patients with diverse malignancies. Many of these new drugs target the human epidermal growth factor receptor (EGFR/HER/ErbB) family of tyrosine kinases, which play a major role in the etiology and progression of many carcinomas, including epithelial ovarian cancer. While several HER-targeted therapeutics are US FDA approved for the treatment of various malignancies, none have gained approval for the treatment of ovarian cancer. Here, we review the published literature on HER-targeted therapeutics for the treatment of ovarian cancer, including novel HER-targeted therapeutics in various stages of clinical development, as well as the challenges that have limited the use of these inhibitors in clinical settings.

AB - Despite decades of research and evolving treatment modalities, survival among patients with epithelial ovarian cancer has improved only incrementally. During this same period, the development of biologically targeted therapeutics has improved survival for patients with diverse malignancies. Many of these new drugs target the human epidermal growth factor receptor (EGFR/HER/ErbB) family of tyrosine kinases, which play a major role in the etiology and progression of many carcinomas, including epithelial ovarian cancer. While several HER-targeted therapeutics are US FDA approved for the treatment of various malignancies, none have gained approval for the treatment of ovarian cancer. Here, we review the published literature on HER-targeted therapeutics for the treatment of ovarian cancer, including novel HER-targeted therapeutics in various stages of clinical development, as well as the challenges that have limited the use of these inhibitors in clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=84858671737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858671737&partnerID=8YFLogxK

U2 - 10.4155/fmc.12.11

DO - 10.4155/fmc.12.11

M3 - Review article

C2 - 22416774

AN - SCOPUS:84858671737

VL - 4

SP - 447

EP - 469

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 4

ER -